

The utility of epigenetic analysis of cfDNA in treating cancer patients

Aviad Zick, M.D., Ph.D. Sharett Institute of Oncology, Hebrew University – Hadassah Medical Center, Jerusalem, Israel.
E-mail – aviadz@hadassah.org.il
Phone – 050-4048024

ISOBM 2022, 16-OCT-2022, Bled

Thank you

Sharett Institute of Oncology; Goldyne Savad Institute for Gene Therapy; Wohl institute for Translational Medicine; Endocrinology and Metabolism Service; Liver Unit, Institute of Gastroenterology and Liver Diseases; Pathology & Surgical department ; Hebrew University – Hadassah Medical Center – S. Abu-Gazala, O. Arieli, E. Carmon, J.E. Cohen, E. Galun, L. Germansky, B. Glaser, A. Grinshpun, A. Hubert, M. Maoz, K. Meir, T. Peretz, D. Planer, R. Safadi, A. Salah, E. Shteyer, M. Temper, B. Uziely, D. Yaish.

Juliet Keidan Institute of Pediatric Gastroenterology Institute, Shaare Zedek Medical Center - A. Ben-Ya'acov.

Department of Surgery A, Kaplan Medical Center, Rehovot, Israel. , Barak Bar Zakai³ , Yael Mavor

Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem Y Dor group – O. Abraham, I. Fox-Fisher, J. Moss, D. Neiman, B.L. Ochana, R. Shemer. B Berman Group – Efrat Katsman, Shari Orlanski, Ilana Fox-Fisher

The Rachel and Selim Benin School of Computer Science and Engineering & The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem – N. Friedman group. Chappleboin, G. Fialkoff, N. J. Gutin, Z. Kamari, T. Kaplan, G. Meler, M. Nitzan, A. Rahat, R. Sadeh, I Sharkia.

Department of Cell and Developmental Biology, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel – Amir Eden

Racah Institute of Physics, Hebrew University, Jerusalem, Israel. - Guy Ron

Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel. – E. Shema group. Vadim Fedyuk Nir Erez , Noa Furth , Olga Beresh

Core Research Laboratory, ISPRO, Florence, Italy – SG. Conticello group. Filippo Martignano

Unit of Respiratory Medicine, Department of Critical Area and Surgical, Medical and Molecular Pathology, University Hospital of Pisa, Pisa, Italy – Iacopo Petrini

SeqLL Inc., Woburn, MA, USA – Ekaterina Andreishcheva , Abhijeet Shinde , Daniel Jones

Supported by Sharett institute fund; ISF, ICRF, The Joint Research Fund between the Hebrew University Faculty of Medicine, and between Hadassah University Hospital, Shaare Tzedek Medical Center, Kaplan Medical Center and Bikur Holim Hospital, UIA, MERCK, Karyopharm & Roche.


Topics

- cfDNA
- Breast methylation patterns in cfDNA
- Inferring expression pattern in cfDNA using cfChIP seq
- Measuring copy number alterations in cfDNA using NANO seq


Overview

- Utilizing cfDNA epigenetic markers to identify different cell types and expression patterns is feasible in an oncological clinical setting.


Chromatin





Cell free DNA (cfDNA)







Breast Specific Methylation Pattern













Immunoprecipitation of chromatin from plasma





cfChIP recaptures the transcriptional program of cells




cfChIP-seq of multiple marks is informative on gene expression




cfChIP is sensitive




cfChIP identifies unique expression patterns in different cancer patients




cfChIP finds a large difference between healthy and colon cancer patients



cfChIP identifies HER2 activation




cfNano: Nanopore shallow WGS detects ctDNA




cfNANO detects copy number alterations in ctDNA


CRC HU008.23




TCGA Common Colorectal Cancer CNA



cfNANO detects *ERBB2* amplifications



cBioPortal allows an integrated view of clinical and pathological information



Conclusion

Epigenetic cfDNA can be used in the clinical setting

Can identify response to chemotherapy

Can identify critical expression patterns such as HER2

Future plans

Integrate Epigenetic cfDNA to routine practice as

- A tumor marker
- A tool for early detection of cancer
- Early detection tissue damage before clinically apparent.

Integrate Epigenetic cfDNA to clinical trials to identify predictive and prognostic markers as well as gain further understanding of the biological mechanisms underlying drug activity.

Thank you very much